This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

POSTER
Olanzapine/Samidorphan Effects on Weight Gain: A Meta-analysis of Phase 2 and 3 Randomized, Double-Blind Studies
Author(s):

Christoph Correll,1-3 Michael J. Doane,4 David McDonnell,5 Meihua Wang,4 Sarah Akerman,4 S. Stephen R. Saklad6

1Zucker Hillside Hospital, Glen Oaks, NY, USA; 2Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; 3Charité Universitätsmedizin, Berlin, Germany; 4Alkermes, Inc., Waltham, MA, USA; 5Alkermes Pharma Ireland Ltd., Dublin, Ireland; 6The University of Texas at Austin, College of Pharmacy, Pharmacotherapy Division, San Antonio, TX, USA

Content available until 05/30/2025